

Massimo Bertinaria

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3608824/massimo-bertinaria-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36 papers	787 citations	17 h-index	27 g-index
45 ext. papers	885 ext. citations	5.5 avg, IF	3.24 L-index

#	Paper	IF	Citations
36	Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. <i>Molecules</i> , 2021 , 26,	4.8	3
35	Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades. <i>Oxidative Medicine and Cellular Longevity</i> , 2020 , 2020, 9219825	6.7	10
34	Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity. <i>Archives of Biochemistry and Biophysics</i> , 2019 , 670, 116-139	4.1	17
33	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1405	5.6	22
32	Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 3656-3671	8.3	95
31	Tu1889 Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation. <i>Gastroenterology</i> , 2016 , 150, S968-S969	13.3	3
30	In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. <i>Pharmacological Research</i> , 2016 , 103, 132-43	10.2	9
29	Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 5271251	6.7	61
28	Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors. <i>ChemMedChem</i> , 2016 , 11, 1790-803	3.7	46
27	NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 7895-9	8.3	15
26	Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 10366-82	8.3	58
25	Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 2107-16	3.4	12
24	A rapid screening for cytochrome P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives. <i>Journal of Biomolecular Screening</i> , 2013 , 18, 211-8		6
23	Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors. <i>ChemMedChem</i> , 2012 , 7, 1647-60	3.7	22
22	Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile. <i>European Journal of Medicinal Chemistry</i> , 2012 , 54, 103-12	6.8	10
21	Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 611-21	8.3	27
20	Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 1757-67	6.8	26

19	A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity. <i>European Journal of Medicinal Chemistry</i> , 2009 , 44, 5071-9	6.8	27
18	Edaravone derivatives containing NO-donor functions. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 574-8	8.3	31
17	Structure-antioxidant activity relationships in a series of NO-donor phenols. <i>ChemMedChem</i> , 2008 , 3, 1443-8	3.7	4
16	Furoxan-, alkyl nitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 7900-7	3.4	37
15	Amphiphilic NO-donor antioxidants. <i>ChemMedChem</i> , 2007 , 2, 234-40	3.7	2
14	Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 5003-11	8.3	22
13	NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 2886-97	8.3	43
12	Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 4750-9	3.4	13
11	Synthesis and antimalarial activities of some furoxan sulfones and related furazans. <i>European Journal of Medicinal Chemistry</i> , 2005 , 40, 1335-40	6.8	32
10	Non-imidazole histamine NO-donor H3-antagonists. <i>Il Farmaco</i> , 2005 , 60, 507-12		5
9	A new class of NO-donor H3-antagonists. <i>Il Farmaco</i> , 2004 , 59, 359-71		11
8	Evidence of self-protonation on the electrodic reduction mechanism of an anti-Helicobacter pylori metronidazole isotere. <i>Journal of Electroanalytical Chemistry</i> , 2004 , 571, 177-182	4.1	8
7	H3 receptor ligands: new imidazole H3-antagonists endowed with NO-donor properties. <i>Il Farmaco</i> , 2003 , 58, 279-83		4
6	Synthesis and anti-Helicobacter pylori properties of NO-donor/metronidazole hybrids and related compounds. <i>Drug Development Research</i> , 2003 , 60, 225-239	5.1	27
5	[3-(1H-imidazol-4-yl)propyl]guanidines containing furoxan moieties: a new class of H3-antagonists endowed with NO-donor properties. <i>Bioorganic and Medicinal Chemistry</i> , 2003 , 11, 1197-205	3.4	21
4	Anti-Helicobacter pylori agents endowed with H2-antagonist properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001 , 11, 403-6	2.9	11
3	Unsymmetrically substituted furoxans. Part 18. Smiles rearrangement in furoxan systems and in related furazans. <i>Journal of the Chemical Society, Perkin Transactions 1</i> , 2001 , 1751-1757		23
2	Synthesis and Pharmacological Characterization of New H2-Antagonists Containing NO-Donor Moieties, Endowed with Mixed Antisecretory and Gastroprotective Activities. <i>Helvetica Chimica Acta</i> , 2000 , 83, 287-299	2	12

- ¹ Antisecretory and gastroprotective activities of compounds endowed with H₂ antagonistic and nitric oxide (NO) donor properties. *Journal of Physiology (Paris)*, **2000**, 94, 5-10